
High-dose intravitreal topotecan (IvitTopo) effectively controlled recurrent retinoblastoma in 13 patients, achieving 92% tumor regression and 100% globe salvage. No complications occurred, indicating its safety and efficacy as an adjunct or potentially stand-alone therapy.
Like
Save
Share